{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:46:27Z","timestamp":1792392387218,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,18]]},"DOI":"10.7759\/cureus.118142","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:24:55Z","timestamp":1792391095000},"source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-Associated Adrenal Insufficiency Presenting as Adrenal Crisis: A Case Report"],"prefix":"10.7759","author":[{"given":"Laura","family":"Samet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Cancer Research UK. Lung Cancer Statistics. (2024). Accessed: September 14, 2026: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/lung-cancer.."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti AK","year":"2021","unstructured":"Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021, 7:1824-32. 10.1001\/jamaoncol.2021.4932","journal-title":"JAMA Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2019.10.2.13","article-title":"Immune-related adverse events from immunotherapy: incorporating care step pathways to improve management across tumor types","volume":"10","author":"Wood LS","year":"2019","unstructured":"Wood LS. Immune-related adverse events from immunotherapy: incorporating care step pathways to improve management across tumor types. J Adv Pract Oncol. 2019, 10:47-62. 10.6004\/jadpro.2019.10.2.13","journal-title":"J Adv Pract Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1044327","article-title":"Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: a systematic review and meta-analysis","volume":"13","author":"Yang B","year":"2023","unstructured":"Yang B, Wang B, Chen Y, et al.. Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: a systematic review and meta-analysis. Front Oncol. 2023, 13:1044327. 10.3389\/fonc.2023.1044327","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir ME","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008, 26:677-704. 10.1146\/annurev.immunol.26.021607.090331","journal-title":"Annu Rev Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of Keynote-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck M","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al.. Updated analysis of Keynote-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019, 37:537-46. 10.1200\/JCO.18.00149","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon EB","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, et al.. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015, 372:2018-28. 10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03491-8","article-title":"Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review","volume":"26","author":"Silva V","year":"2024","unstructured":"Silva V, Matos C. Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review. Clin Transl Oncol. 2024, 26:2431-43. 10.1007\/s12094-024-03491-8","journal-title":"Clin Transl Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun DJ","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017, 13:195-207. 10.1038\/nrendo.2016.205","journal-title":"Nat Rev Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.22541\/au.175248753.34158735\/v1","article-title":"Unmasking adrenal crisis: A review of pembrolizumab and its immune-related adverse events [PREPRINT]","author":"Singh S","year":"2025","unstructured":"Singh S, Fitch B, Nweke C, et al.. Unmasking adrenal crisis: A review of pembrolizumab and its immune-related adverse events [PREPRINT]. Authorea. 2025, 10.22541\/au.175248753.34158735\/v1","journal-title":"Authorea"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000505687","article-title":"A case of isolated adrenocorticotropic hormone deficiency caused by pembrolizumab","volume":"13","author":"Bekki T","year":"2020","unstructured":"Bekki T, Takakura Y, Kochi M, et al.. A case of isolated adrenocorticotropic hormone deficiency caused by pembrolizumab. Case Rep Oncol. 2020, 13:200-6. 10.1159\/000505687","journal-title":"Case Rep Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-024-00332-2","article-title":"Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report","volume":"10","author":"Fujimiya T","year":"2024","unstructured":"Fujimiya T, Azuma K, Togashi Y, Kuwata K, Unezaki S, Takeuchi H. Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report. J Pharm Health Care Sci. 2024, 10:10. 10.1186\/s40780-024-00332-2","journal-title":"J Pharm Health Care Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41049","article-title":"Pembrolizumab-induced adrenal insufficiency presenting eight months after cessation of treatment","volume":"15","author":"Zilberman S","year":"2023","unstructured":"Zilberman S, Rafii DC, Giunta J. Pembrolizumab-induced adrenal insufficiency presenting eight months after cessation of treatment. Cureus. 2023, 15:e41049. 10.7759\/cureus.41049","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1807486","article-title":"Adrenal crisis","volume":"381","author":"Rushworth RL","year":"2019","unstructured":"Rushworth RL, Torpy DJ, Falhammar H. Adrenal crisis. N Engl J Med. 2019, 381:852-61. 10.1056\/NEJMra1807486","journal-title":"N Engl J Med"},{"key":"ref15","article-title":"Adrenal Crisis","author":"Elshimy G","year":"2025","unstructured":"Elshimy G, Chippa V, Kaur J, Jeong JM. Adrenal Crisis. StatPearls, Treasure Island, FL; 2025."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0824","article-title":"Extensive expertise in endocrinology. Adrenal crisis","volume":"172","author":"Allolio B","year":"2015","unstructured":"Allolio B. Extensive expertise in endocrinology. Adrenal crisis. Eur J Endocrinol. 2015, 172:R115-24. 10.1530\/EJE-14-0824","journal-title":"Eur J Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c150015","article-title":"Regulation of the hypothalamic-pituitary-adrenocortical stress response","volume":"6","author":"Herman JP","year":"2016","unstructured":"Herman JP, McKlveen JM, Ghosal S, et al.. Regulation of the hypothalamic-pituitary-adrenocortical stress response. Compr Physiol. 2016, 6:603-21. 10.1002\/cphy.c150015","journal-title":"Compr Physiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye ES","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, et al.. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022, 187:G1-21. 10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"},{"key":"ref19","unstructured":"Royal College of Physicians. prevention and emergency management of adult patients with adrenal insufficiency. (2020). Accessed: September 2026: https:\/\/www.rcp.ac.uk\/resources\/prevention-and-emergency-management-of-adult-patients-with-adrenal-insufficiency\/.."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/538783-pembrolizumab-associated-adrenal-insufficiency-presenting-as-adrenal-crisis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:24:58Z","timestamp":1792391098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/538783-pembrolizumab-associated-adrenal-insufficiency-presenting-as-adrenal-crisis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,18]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.118142","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,18]]}}}